OBJECTIVES: The present trial investigated the efficacy and safety of @entity16960 in the prevention of arterial @entity1031 after an @entity583 ( @entity583 ). BACKGROUND: Left ventricular (LV) @entity715 formation is associated with increased risk of @entity1416 in @entity1 with an acute @entity583 . Thrombolytic and antiplatelet therapy do not prevent @entity715 formation. METHODS: A total of 776 @entity1 were enrolled in a multicenter, randomized, double-blind, placebo-controlled trial of subcutaneous @entity16960 (150 IU/kg body weight every 12 h during the hospital period). Thrombolytic therapy and @entity117 were administered in 91.5% and 97.6% of @entity1 , respectively. The primary study end point was the composite of @entity715 formation diagnosed by echocardiography and @entity1416 on day 9 +/- 2. RESULTS: Of 517 @entity1 with echocardiographic recordings available for end point analysis, @entity715 formation or @entity887 , or both, was found in 59 (21.9%) of 270 @entity1 (59 with @entity715 , none with @entity887 ) in the placebo group and 35 (14.2%) of 247 @entity1 (34 with @entity715 , 1 with @entity887 ) in the @entity16960 group (p = 0.03). The risk reduction of @entity715 formation associated with @entity16960 treatment was 0.63 (95% confidence interval 0.43 to 0.92, p = 0.02). Analyses of all randomized @entity1 (388 in each group) revealed no significant difference between the placebo and @entity16960 groups with respect to @entity1416 (6 vs. 5 @entity1 ), reinfarction (8 vs. 6 @entity1 ) and mortality rates (23 vs. 23 @entity1 , p = NS for all). @entity16960 was associated with an increased risk of @entity548 : major in 11 @entity16960 group @entity1 (2.9%) verus 1 placebo group @entity1 (0.3%, p = 0.006); minor in 52 @entity16960 group @entity1 (14.8%) versus 8 placebo group @entity1 (1.8%, p < 0.001). CONCLUSIONS: @entity16960 treatment significantly reduces LV @entity715 formation in acute anterior @entity583 but is associated with increased hemorrhagic risk.

Randomized trial of low molecular weight heparin ( @entity16960 ) in prevention of left ventricular thrombus formation and arterial embolism after XXXX : the Fragmin in Acute @entity583 (FRAMI) Study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity583 :: ('MESH:D009203', 'Disease') :: ['MI', 'acute anterior myocardial infarction'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity16960 :: ('MESH:D017985', 'Chemical') :: ['Dalteparin', 'dalteparin'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1416 :: ('MESH:D020762', 'Disease') :: ['arterial embolism'] @entity887 :: ('MESH:D004617', 'Disease') :: ['embolism'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']
@entity583 :: (MESH:D009203,Disease) :: ['acute anterior myocardial infarction']
